Videos

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team. 


Dr. Jeffrey Trent on the Melanoma Dream Team

Articles

$12 million in grants pursued by TGen-George Mason Molecular Medicine Alliance, leveraging institutes' expertise in genomics and proteomics.

TGen and George Mason University Announce Precision Medicine Alliance for Patients With Serious Illnesses

Ramesh K. Ramanathan, MD, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.

Dr. Ramanathan on Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.

Nab-Paclitaxel Boosts Survival in Pancreatic Cancer

The ability of clinicians to improve treatment outcomes that gemcitabine offers for patients with metastatic pancreatic cancer is expected to move forward now that the FDA has approved a new indication for nab-paclitaxel (Abraxane) as part of a combination regimen, according to researchers.

New Indication Solidifies Nab-Paclitaxel Pancreatic Regimen

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

tgen

Latest from tgen

New content coming soon, please check back later.